Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis

Background: This study investigates the potential predictors of nivolumab plus chemotherapy or multitarget tyrosine kinase inhibitor (TKI) treatment response in patients with recurrent hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Methods: Patients with recurrent hepatitis B virus-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Chen, Chao, An, Li, Cheng, Ying, Luo, Xianwen, Li, Zixiong, Liu, Xiufeng
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7479184/
https://ncbi.nlm.nih.gov/pubmed/32983970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01404
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados